AI vs. COVID-19 in drug discovery

April 21, 2020 | Case Study

COVID-19, caused by SARS-Cov-2, has transformed daily life across the globe in a few short months and has unleashed a scientific race to restore the economy and save patients. With the speed of COVID-19's spread and its associated social and economic impact, an effective and speedy solution is required. As a result, scientists have been unleashing AI and big data on COVID-19 to find drugs to treat it and vaccines to prevent it. AI in drug discovery has been under development for more than a decade to bring down drug development costs, which increased on average to more than $2.5 billion – a greater than 25× increase over the past 30 years.

Related companies	IBM, Exscientia, Diamond Light Source, Calibr

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Interested in Learning More?

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978